MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Company (“MedX” or the “Company”) (TSX-V: MDX) a world leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX’s integrated skin assessment teledermatology platform offered in four clinics across Ontario beginning in late June, with plans to a wider market rollout in Canada and the United States later this year. The first four clinics will be located in London, Ottawa, Port Elgin and Sarnia.
“With only about 500 dermatologists available to serve more than 37 million Canadians, wait times to see a dermatologist in person can range from five months to a year,” said Sylvain Desjeans, Chief Revenue Officer of MedX. “The COVID-19 pandemic has almost doubled the average waiting period. We know that detecting melanoma early dramatically increases patient survival and reduces costs to the healthcare system. Increasing accessibility to digitization through a partnership with VidaCeuticals and its extensive network of clinical partners will help us work towards the early detection of skin cancer.
Alignment with company values and passion to save lives led VidaCeuticals Health Products Inc. to connect with MedX to support a strategic and aggressive distribution plan to reach more North Americans with MedX’s technology – its SIAscope™ imaging device and the DermSecure™ cloud-based telemedicine platform.
“We share values and a passion for finding easy-to-access solutions that ultimately improve and save lives, avoiding unnecessary health impacts on families and communities,” explained Jean-Guy. Bourguignon, Managing Director of VidaCeuticals Health Products Inc. “VidaCeuticals looks forward to growing with MedX to expand into Canada and the United States with a mission to increase access to skin screening and lesion assessment, improving and patient outcomes.
According to the Canadian Dermatology Association, last year about 8,000 Canadians were diagnosed with melanoma and about 1,300 Canadians died from it. With mortality rates increasing by up to 1.2% per year since 1984, early and rapid detection is key to improving patient outcomes.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, using its SIAscopy™ technology. SIAscopy™ is also integrated into its SIAMETRICS™ products, a well-regarded research system used to assess the effectiveness of treatment for a variety of skin conditions, including burns. The SIAscope™ and the company’s other devices are manufactured in its ISO 13485 certified facility. The SIAscope™ is a handheld device that uses patented technology using light and its delivery to see up to 2mm below moles and lesions moles in a painless and non-invasive way, with its software then creating real-time images for doctors and dermatologists to assess all types of moles or lesions in seconds. These products are Health Canada, FDA, TGA and CE approved for use in Canada, USA, Australia, New Zealand, European Union, Turkey and Brazil. DermSecure™ meets all relevant privacy, security and regulatory requirements in Canada, USA, Brazil and EU. MedX also designs, manufactures and distributes quality therapeutic and dental photobiomodulation lasers to provide drug-free, non-invasive treatment of tissue damage and pain. www.medxhealth.com
About VidaCeuticals Health Products
VidaCeuticals Health Products Inc. focuses on connecting people with innovative health solutions, with an emphasis on delivering exclusive and innovative product lines and devices, helping people achieve longevity through a healthier quality of life too naturally as possible. Visit: www.VidaCeuticals.com
This press release does not constitute an offer of securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities laws. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and loss history, the inability to obtain successful additional financings, the inability to raise capital on terms acceptable to the business, the inability to compete in the market, the inability to complete the proposed acquisition and any other risks that may cause actual results materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements contained in this press release are based on information available to the Company as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date hereof. date of this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
